AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

IVERIC bio to Report First Quarter 2019 Financial Results and Host Conference Call on Wednesday, May 8, 2019

May 1, 2019

NEW YORK--(BUSINESS WIRE)--May 1, 2019--IVERIC bio (Nasdaq:ISEE) today announced that it will report its first quarter 2019 financial and operating results on Wednesday, May 8, 2019. Following the announcement, IVERIC bio’s management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a general business update.

To participate in this conference call, dial 888-224-1005 (USA) or 323-794-2551 (International), passcode 9765307. A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the IVERIC bio website at www.ivericbio.com. A replay will be available approximately two hours following the live call for two weeks. The replay number is 888-203-1112 (USA Toll Free), passcode 9765307.

About IVERIC bio

IVERIC bio is a biotechnology company with a focus on the discovery and development of novel gene therapy solutions to treat orphan inherited retinal diseases with unmet medical needs. Vision is Our Mission. For more information on the Company’s gene therapy and other programs, please visit  www.ivericbio.com.

Forward-looking Statements

Any statements in this press release about IVERIC bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent IVERIC bio’s views only as of the date of this press release. IVERIC bio anticipates that subsequent events and developments will cause its views to change. While IVERIC bio may elect to update these forward-looking statements at some point in the future, IVERIC bio specifically disclaims any obligation to do so.

ISEE-G

View source version on businesswire.com:https://www.businesswire.com/news/home/20190501005023/en/

CONTACT: Investor:

Kathy Galante

IVERIC bio

Vice President, Investor Relations and Corporate Communications

212-845-8231

kathy.galante@ivericbio.com

Media:

Alex Van Rees

SmithSolve LLC on behalf of IVERIC bio

973-442-1555 ext. 111

alex.vanrees@smithsolve.com

KEYWORD: UNITED STATES NORTH AMERICA NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS OPTICAL PHARMACEUTICAL OTHER HEALTH RESEARCH OTHER SCIENCE FDA SCIENCE

SOURCE: IVERIC bio

Copyright Business Wire 2019.

PUB: 05/01/2019 08:00 AM/DISC: 05/01/2019 08:01 AM

http://www.businesswire.com/news/home/20190501005023/en